Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryosurgery and NK Immunotherapy for Advanced Esophageal Cancer
NCT02843581Phase 2Completed
- Sponsor
- Fuda Cancer Hospital
- Start
- Jul 2016
- Primary completion
- Jul 2017
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Natural Killer Cells in esophageal cancer (2 arms), sponsored by Fuda Cancer Hospital. Primary endpoint: Relief degree at 3 months. Started Jul 2016; status: completed.
02
Drugs
Natural Killer Cells
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT02843581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02843581.